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Cardiovascular Surgery
Patterns of Use of Perioperative Angiotensin-Converting
Enzyme Inhibitors in Coronary Artery Bypass Graft
Surgery With Cardiopulmonary Bypass
Effects on In-Hospital Morbidity and Mortality
Benjamin Drenger, MD*; Manuel L. Fontes, MD*; Yinghui Miao, MD, MPH; Joseph P. Mathew, MD;
Yaacov Gozal, MD; Solomon Aronson, MD, FCCP; Cynthia Dietzel, MD;
Dennis T. Mangano, PhD, MD; for the Investigators of the Ischemia Research and Education
Foundation and the Multicenter Study of Perioperative Ischemia Research Group
Background—Despite proven benefit in ambulatory patients with ischemic heart disease, the pattern of use of
angiotensin-converting enzyme inhibitors (ACEIs) in coronary artery bypass graft surgery has been erratic
and controversial.
Methods and Results—This is a prospective observational study of 4224 patients undergoing coronary artery bypass graft
surgery. The cohort included 1838 patients receiving ACEI therapy before surgery and 2386 (56.5%) without ACEI
exposure. Postoperatively, the pattern of ACEI use yielded 4 groups: continuation, 915 (21.7%); withdrawal, 923
(21.8%); addition, 343 (8.1%); and no ACEI, 2043 (48.4%). Continuous treatment with ACEI versus no ACEI was
associated with substantive reductions of risk of nonfatal events (adjusted odds ratio for the composite outcome, 0.69;
95% confidence interval, 0.52–0.91; P0.009) and a cardiovascular event (odds ratio, 0.64; 95% confidence interval,
0.46–0.88; P0.006). Addition of ACEI de novo postoperatively compared with no ACEI therapy was also associated
with a significant reduction of risk of composite outcome (odds ratio, 0.56; 95% confidence interval, 0.38–0.84;
P0.004) and a cardiovascular event (odds ratio, 0.63; 95% confidence interval, 0.40–0.97; P0.04). On the other
hand, continuous treatment of ACEI versus withdrawal of ACEI was associated with decreased risk of the composite
outcome (odds ratio, 0.50; 95% confidence interval, 0.38–0.66; P0.001), as well as a decrease in cardiac and renal
events (P0.001 and P0.005, respectively). No differences in in-hospital mortality and cerebral events were noted.
Conclusions—Our study suggests that withdrawal of ACEI treatment after coronary artery bypass graft surgery is
associated with nonfatal in-hospital ischemic events. Furthermore, continuation of ACEI or de novo ACEI therapy early
after cardiac surgery is associated with improved in-hospital outcomes. (Circulation. 2012;126:261-269.)
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Mortality from coronary artery bypass (CABG) surgeryhas become infrequent with an incidence as low as
2%1,2; however, the occurrence of nonfatal cardiovascular
events remains unacceptably high.3–5 Over the past decade,
several classes of antiischemic agents, including statins,
-blockers, and platelet inhibitors, have emerged as stan-
dard therapies for mitigating perioperative cardiovascular
complications.6 –10
Editorial see p 249
Clinical Perspective on p 269
The renin-angiotensin-aldosterone system (RAAS) be-
comes hyperactive during and after cardiopulmonary bypass
(CPB) and is likely an important mediator of microvascular
ischemic injury, as was also demonstrated in ischemia/
reperfusion injury and during sepsis.11,12 It is known that
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long-term overexposure of tissue angiotensin-converting en-
zyme (ACE) alters the angiotensin II/bradykinin balance,
resulting in endothelial dysfunction.13,14 Angiotensin II pro-
motes numerous vascular deleterious effects, including in-
flammation, thrombosis, apoptosis, atherosclerosis, fibrosis,
and plaque rupture.15 Thus, antagonism of the RAAS with
either ACE inhibitors (ACEIs) or angiotensin receptor block-
ers may afford additive cardioprotection to aspirin and
statins.16 Furthermore, with the intense inflammatory re-
sponse of the CPB involving platelet activation, the prophy-
lactic antiinflammatory and antiaggregate capacity of ACEI
may afford protection against cerebrovascular13,17,18 and re-
nal19,20 adverse events and reduce other perioperative vascu-
lar complications in CABG surgery. Unfortunately, perioper-
ative use of ACEI has been plagued with controversy,
primarily because of historical reports linking it to protracted
vasoplegia before, during, and after CPB.21–23 Consequently,
in the setting of surgery, its pattern of practice, both in the
United States and internationally, is uncertain, and cessation
of ACEI therapy may be as detrimental as statin and
-blocker withdrawal.24,25 Therefore, the International Mul-
ticenter Study on Perioperative Ischemia (McSPI)–Epidemi-
ology II (EPI-II) Research Group sought to prospectively
characterize the pattern of perioperative ACEI use in patients
having CABG surgery with CPB, to describe related hemo-
dynamic effects, and to determine the association between the
timing of ACEI renewal and in-hospital fatal and nonfatal
vascular events.
Methods
Study Design
The Ischemia Research and Education Foundation (IREF)/McSPI
EPI-II is a prospective and longitudinal study that prospectively
enrolled 5436 patients from 72 medical institutions among 17
countries in North America, South America, Europe, the Middle
East, and Asia who were admitted for CABG surgery using CPB.
After individual Institutional Review Board approval was obtained,
each center prospectively enrolled up to 100 patients according to a
systematic random sampling scheme and after each patient signed a
written informed consent. The methods of this study have been
previously described in detail and are briefly summarized here.9
Data Collection and Management
For each enrolled patient, independent investigators collected7500
fields of data; treating physicians were blinded to all research data.
Clinical decisions were not controlled by study protocol. Once
completed, the case report form was sent to the data coordinating
center where the data were examined for completeness and accuracy,
with all changes documented before database closure.
Outcomes Measures
All outcomes were prespecified, defined by protocol, and discerned
by investigators blinded to treatment group. Preoperative left ven-
tricular dysfunction and staging of congestive heart failure (CHF)
were defined in detail by entries in the case report form. Fatal and
nonfatal outcomes occurring 48 hours after surgery and during the
index hospitalization were classified as cardiac (myocardial infarc-
tion [MI], CHF, or death resulting from cardiac causes), cerebral
(stroke, encephalopathy, or death resulting from stroke), renal
(dysfunction, failure), or other (such as gastrointestinal, infectious,
pulmonary, or death resulting from any other cause).9 The primary
outcome of the study was defined as the composite outcome of the
cardiac, cerebral, and renal events and in-hospital mortality.
Myocardial ischemia was defined as postoperative angina or
ischemia detected by the clinician. The diagnosis of MI required the
development of either new Q waves or new persistent ST-segment or
T-wave changes associated with an elevation of creatine kinase-MB
isoenzyme values or autopsy evidence of acute MI. The diagnosis of
heart failure after surgery required signs and symptoms by physical
examination and monitoring devices, the use of continuous nonrou-
tine inotropic support for at least 24 hours, the use of a ventricular
assist device, or autopsy evidence of heart failure. Cerebral outcomes
were classified as clinically diagnosed stroke or encephalopathy or
computed tomography, magnetic resonance imaging, or autopsy
evidence of a focal or global defect. Stroke was defined by new onset
of stroke, stupor, coma, encephalopathy, transient ischemic attack, or
seizures in the postoperative period. The National Institute of Health
Stroke Scale was used to assess stroke severity. Renal dysfunction
was defined as a postoperative serum creatinine level of at least 2.0
mg/dL (177 mol/L) accompanied by an increase of at least 0.7
mg/dL (62 mol/L) from baseline.4,6,9 Postoperative creatinine
records were collected at 8 different time points, and the maximum
value was extracted. Renal failure was defined as dysfunction
requiring dialysis or autopsy evidence of renal failure. Death was
defined as death before hospital discharge.
Medications of the ACEI and angiotensin receptor blocker groups
taken by the patients included benazepril, captopril, enalapril, fosi-
nopril, lisinopril, losartan, moexipril, perindopril, quinapril, ramipril,
and spirapril, and others. These were recorded and grouped by class
in the case report form. Timing of the last dose before surgery and
the timing of initiation of ACEI therapy after surgery were recorded,
as well as all the antiischemic drugs and other medications. For an
outcome to be counted as an event, it must have occurred after the
administration or withdrawal of the drug. Blood pressure measure-
ments during surgery included highest and lowest values before,
during, and after CPB (systolic and mean blood pressures every 15
minutes for the first 4 hours postoperatively and every hour in the
remaining first 24 hours). For patients with pulmonary artery
catheter, derived data, including cardiac output, were recorded
hourly in the intensive care unit (ICU).
Study Sample
In all, 5436 patients were enrolled in the EPI-II study. We excluded
371 for the following reasons: 32 withdrew from the study before
surgery; 2 died before surgery; 97 did not undergo surgery or surgery
was rescheduled; 132 did not undergo CPB; 11 were enrolled in
another clinical trial; and 97 had incomplete data. Of the remaining
5065 patients to be evaluated, 841 were excluded from the study: 555
had valve surgical procedure, 147 had other cardiac surgical proce-
dures, 119 had other noncardiac surgical procedures, 61 had concur-
rent emergent surgery, and 43 died in the first 48 postoperative hours
(15 had emergent surgery or another surgery besides CABG; of the
28 patients who had only CABG surgery, 17 were not on ACEI and
11 were on ACEI preoperatively). Thus, 4224 patients remained,
including 1838 treated preoperatively with ACEI and 2386 not
treated (Figure 1). After surgery, 4 groups emerged: a continuation
group consisting of patients who were on ACEI preoperatively and
postoperatively; a withdrawal group comprising patients who were
taking ACEI preoperatively but not postoperatively; an addition
group consisting of patients who were not on ACEI preoperatively
but had it added postoperatively; and a no ACEI group that included
patients who did not have any exposure to ACEI.
Statistical Methods
Baseline characteristics and operative factors were compared be-
tween patients receiving and those not receiving ACEI preopera-
tively. Continuous variables were summarized with medians and the
25th and 75th percentiles, and the Wilcoxon rank-sum test was used
for comparisons. Categorical data were summarized by frequencies
and percentages, and the 2 test or Fisher exact test was applied to
compare patients between study groups.
We used the propensity score adjustment method to control for
confounding. Applying nonparsimonious logistic regression models,
we developed propensity score as the probability of receiving ACEI
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treatment (versus no treatment) given all the baseline variables,
including demographic, medical history, surgical, intraoperative, and
early postoperative characteristics, as well as treatment selection
covariates (see the online-only Data Supplement). The area under the
receiver-operating characteristic curve, referred to as the C index,
was used to assess the discriminate power of the propensity score.
The propensity score of receiving ACEI treatment was calculated in
3 subgroups: no ACEI and ACEI continuation, ACEI continuation
and withdrawal, and no ACEI and ACEI addition, separately. The
derived propensity scores were then used for multivariable covariate
adjustment, together with the ACEI treatment indicator variables and
Acute Physiology and Chronic Health Evaluation II (APACHE II)26
Acute Physiology score (partial), which was used to determine the
severity of illness within the first 24 hours after each patient was
admitted to the ICU. The C index was 0.80 for the propensity score
model of ACEI continuation versus no ACEI, 0.71 for ACEI
continuation versus withdrawal, and 0.76 for ACEI addition versus
no ACEI.
Kaplan–Meier survival analysis was used to examine the dif-
ferences in unadjusted 30-day event-free status (in-hospital)
among the 4 ACEI treatment groups, with the log-rank test used
for comparisons.
The multivariable logistic regression analysis of the composite
outcome included the following predictor variables: demographic,
medical history, surgical/intraoperative/early postoperative factors,
risk indexes, and ACEI treatment groups. A stepwise (backward and
forward) variable selection procedure was applied to identify vari-
ables associated with the composite outcome. Model entry and
retention criteria were set at P0.20 and P0.05, respectively.
All statistical analyses were performed with SAS statistical
software version 8.2 (SAS Institute Inc, Cary, NC). Statistical
significance was set at P0.05 (2 tailed).
Results
The demographic and surgical characteristics of patients
presenting on ACEI therapy versus no ACEI therapy are
presented in Table 1.27 Patients who were not treated with
ACEI compared with patients on ACEI treatment before
surgery had fewer preoperative cardiovascular risk factors
such as hypertension, CHF, and MI and other diseases such as
renal disease, diabetes mellitus, and pulmonary and liver
disease. Intraoperative clinical and surgical characteristics
were similar between the 2 groups except for the duration of
CPB and cross-clamp times, which were prolonged in the
ACEI group (P0.001).
ACEI Therapy and Clinical Outcomes
Table 2 presents adjusted odds ratio for fatal and nonfatal
cardiovascular outcomes for group comparisons. Results of
the multivariable analysis of composite outcomes including
ACEI treatment groups (continuation versus no ACEI, con-
tinuation versus withdrawal; addition versus no ACEI) are
presented in Table 3.
ACEI Continuation Versus No ACEI
After adjustments for both propensity score and APACHE II,
continuous treatment with ACEI was associated with a 31%
(P0.009) lower odds of developing the composite outcome
and a 36% (P0.006) lower odds of a cardiovascular event
(38% and 37% lower in CHF and MI; P0.05 and P0.03,
respectively). Additionally, when we included continuous
ACEI versus No ACEI treatment as a variable in our
multivariable regression analysis (Table 3), it emerged as an
independent correlate of composite outcomes (adjusted OR
[95% CI], 0.58 [0.44–0.76]; P0.001).
No significant differences in surgical characteristics were
noted. During the first 24 hours in the ICU, the 2 groups had
similar median cardiac outputs and a small difference in
median systolic blood pressure of 5 mm Hg (Table 4), lower
in the ACEI continuation group (P0.001), whereas the use
of 2 nonroutine vasopressors was twice as high compared
with the no ACEI group (P0.001).
ACEI Continuation Versus Withdrawal
Half of the patients (923 of 1838) treated with ACEI
preoperatively had it stopped postoperatively. Continuous
Figure 1. Diagram of patient enrollment through the study. For patients who had postoperative outcome events, postoperative angio-
tensin-converting enzyme inhibitor (ACEI) therapy was defined as postoperative ACEI medication before or on the same day as the
occurrence of the first postoperative composite outcome; for patients who did not have postoperative outcome events, postoperative
ACEI therapy was defined as ACEI treatment after coronary artery bypass graft (CABG) surgery. EPI-II indicates International Multi-
center Study on Perioperative Ischemia (McSPI)–Epidemiology II.
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Table 1. Baseline Characteristics of 4224 Study Patients by Angiotensin-Converting Enzyme Inhibitor
Treatment Groups
Characteristics
Patients Not Receiving
ACEI on Admission or
Preoperatively (n2386)
Patients Receiving
ACEI on Admission or
Preoperatively (n1838) P
Age, y
Median 63.5 64.5 0.02
Interquartile range 56.8–70.1 56.9–71.2
Women, n (%) 419 (17.6) 377 (20.5) 0.02
Medical history, n (%)
Unstable angina 1269 (53.2) 932 (50.7) 0.11
Congestive heart failure with hospitalization 109 (4.6) 237 (12.9) 0.001
Myocardial infarction within 90 d 253 (10.6) 402 (21.9) 0.001
Dysrhythmia 336 (14.1) 390 (21.2) 0.001
Hypertension 1395 (58.5) 1456 (79.2) 0.001
Valve disease 143 (6.0) 191 (10.4) 0.001
CABG 130 (5.4) 101 (5.5) 0.95
Neurologic dysfunction (stroke/TIA) 210 (8.8) 226 (12.3) 0.001
Syncope 130 (5.4) 129 (7.0) 0.04
Creatinine on admission (maximum) 1.3 mg/dL 305 (12.8) 371 (20.2) 0.001
Renal disease 297 (12.5) 354 (19.3) 0.001
Dialysis 12 (0.5) 4 (0.2) 0.14
Peripheral vascular disease 347 (14.5) 364 (19.8) 0.001
Diabetes mellitus 596 (25.0) 692 (37.6) 0.001
Hypercholesterolemia (without treatment) 516 (21.6) 387 (21.1) 0.65
Surgical, intraoperative, or early postoperative factors
Bypass pump flow, n (%) 0.91
Pulsatile 328 (13.7) 255 (13.9)
Nonpulsatile 2058 (86.3) 1583 (86.1)
Cardiopulmonary bypass time, min 0.001
Median 89 95
Interquartile range 69–112 74–118
Cross-clamp time, minute 0.001
Median 54 57
Interquartile range 40–71 42–74
Fluid intake intraoperative to RDOS, mL 0.001
Median 7170 7499
Interquartile range 5850–8717 5950–9260
Medication, nonroutine— inotropes/vasoconstrictors
intraoperative or on RDOS
1117 (46.8) 1119 (65.2) 0.001
Intubation and re-intubation 24 h (within 48 h) 272 (11.5) 322 (17.7) 0.001
Assist device use for low cardiac output or ischemic
or angina intraoperative or on RDOS
40 (1.7) 47 (2.6) 0.05
Risk index
EuroSCORE 0.001
Median 3 4
Interquartile range 1–5 2–6
APACHE II–Acute Physiology Score (partial) 0.001
Median 4 5
Interquartile range 3–6 3–7
ACEI indicates angiotensin-converting enzyme inhibitor; CABG, coronary artery bypass grafting; TIA, transient ischemic attack; RDOS,
remaining day of surgery; EuroSCORE27, European System for Cardiac Operative Risk Evaluation; and APACHE II, Acute Physiology and
Chronic Health Evaluation II. The 2-group comparison is between preoperative ACEI treatment and no preoperative ACEI treatment.
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treatment with ACEI was associated with substantive lower
odds of developing a composite outcome and a cardiovascu-
lar event (Tables 2 and 3). On the other hand, the withdrawal
group showed an adjusted 127% and 113% higher odds in
cardiac and renal events (P0.001 and P0.005, respec-
tively). Surgical characteristics and ICU events were similar
between these 2 groups except for few notable differences as
shown in Table 4. Namely, median cardiac outputs, need for
2 nonroutine inotropes (first 24 hours postoperatively), and
extubation times were comparable, whereas small differences
were noted in mean systolic blood pressure (4.9 mm Hg
lower in the withdrawal group; P0.001) and red blood cell
transfusion rates (40% versus 48%; P0.001). In addition to
lower blood pressure and higher transfusion rates, the use of
an assist device for low cardiac output intraoperatively was 3
times higher for the withdrawal group.
ACEI Addition Versus No ACEI
Addition of ACEI therapy postoperatively de novo was
uncommon, prescribed in 14.4% (343 of 2386) of patients.
After propensity score and APACHE II adjustments, addition
of ACEI was associated with a 44% lower odds in composite
outcome (P0.004), driven entirely by a 37% lower odds in
cardiovascular event. No difference in surgical characteristics
was noted, but time on mechanical ventilator was less in the
addition group (13.2 versus 16.4 hours; P0.001) and sys-
tolic blood pressure was higher by 5.6 mm Hg (Table 4).
Event-Free Survival
The 1-month event-free status after CABG surgery, as esti-
mated by the Kaplan–Meier survival curve, indicated that the
withdrawal group had the poorest outcome (P0.001; Figure
2), with only 71% of the patients being event free. Compared
with the other 3 groups, the cumulative composite outcome in
the withdrawal group was doubled.
Discussion
In the setting of CABG surgery with CPB, the pattern of
perioperative ACEI use was associated with in-hospital fatal
and nonfatal vascular outcomes. Treatment with ACEI before
and early after surgery was associated with a significantly
lower risk of cardiovascular and overall composite events; de
novo addition of ACEI therapy postoperatively was related to
a lowering of odds in overall composite outcomes by nearly
one half; and notably, withdrawal of ACEI treatment after
surgery was associated with significant rise in odds of cardiac
and renal ischemic events.
In ambulatory patients with coronary artery disease, treat-
ment with ACEI is common and associated with improve-
ment in morbid and fatal vascular outcomes.28,29 Whether
perioperative use of ACEI confers acute and clinically rele-
vant vascular protection is an important question that we
sought to answer in the present study. Also of interest was the
association of immediate ACEI withdrawal after CABG
surgery. Forty-three percent of our patients were receiving
ACEI preoperatively, which was stopped the day before
surgery; however, half of this cohort was subjected to
immediate withdrawal of ACEI therapy postoperatively. The
use of ACEI was associated mostly with better cardiac
outcome, with a nearly 40% reduction in odds of both
postoperative CHF and MI. Overall, we observed a 31%
reduction of odds in the composite outcome (death, cardio-
vascular, and renal events) in those patients receiving preop-
erative and postoperative ACEI compared with no therapy.
Similarly, de novo use of ACEI postoperatively was associ-
ated with a 44% reduction in odds in composite outcome.
In a cohort of patients requiring coronary revascularization,
Kjøller-Hansen et al30 also found that the addition of oral
ramipril 5 to 7 days after surgery and continued for a medium
follow-up of 2.5 years was associated with a 58% reduction in
the composite end point of cardiac death, acute MI, or CHF.
In a double-blind trial, Oosterga et al31 in the QUinapril On
Vascular ACE and Determinants of ISchemia (QUO VADIS)
study used oral quinapril (40 mg/d) 1 month before CABG
surgery and postoperatively for 1 year and reported a signif-
icant reduction in recurrent angina. According to our find-
Table 2. Adjusted Effect of Angiotensin-Converting Enzyme Inhibitor Treatment on Outcome Events
Effect of ACEI Treatment: Continuation vs No ACEI Effect of ACEI Treatment: Continuation vs Withdrawal Effect of ACEI Treatment: Addition vs No ACEI
Outcome Event
Incidence
of Outcome in
the No ACEI Group
(n1765), n (%)
Adjusted
OR (95% CI)*
Incidence
of Outcome in the
Continuation Group
(n798), n (%) P
Adjusted
OR 95% CI)*
Incidence
of Outcome in
the Withdrawal Group
(n764), n (%) P
Adjusted
OR (95% CI)*
Incidence of
Outcome in the
Addition Group
(n311), n (%) P
Composite outcome 249 (14.1) 0.69 (0.52–0.91) 102 (12.8) 0.009 0.50 (0.38–0.66) 215 (28.1) 0.001 0.56 (0.38–0.84) 36 (11.6) 0.004
In-hospital death 15 (0.8) 0.95 (0.41–2.22) 12 (1.5) 0.91 0.63 (0.29–1.35) 23 (3.0) 0.23 1.49 (0.53–4.19) 6 (1.9) 0.45
Cardiovascular event 192 (10.9) 0.64 (0.46–0.88) 69 (8.7) 0.006 0.44 (0.32–0.61) 171 (22.4) 0.001 0.63 (0.40–0.97) 28 (9.0) 0.04
Congestive heart
failure
87 (4.9) 0.62 (0.39–0.99) 32 (4.0) 0.05 0.39 (0.26–0.61) 102 (13.4) 0.001 0.62 (0.34–1.14) 14 (4.5) 0.13
Myocardial
infarction
121 (6.9) 0.63 (0.42–0.95) 40 (5.0) 0.03 0.54 (0.36–0.82) 86 (11.3) 0.004 0.61 (0.35–1.06) 16 (5.1) 0.08
Cerebrovascular
event
30 (1.7) 1.26 (0.67–2.38) 23 (2.9) 0.47 0.62 (0.36–1.08) 46 (6.0) 0.09 0.76 (0.33–1.75) 8 (2.6) 0.51
Renal event 43 (2.4) 0.71 (0.40–1.27) 25 (3.1) 0.25 0.47 (0.28–0.79) 59 (7.7) 0.005 0.57 (0.24–1.36) 8 (2.6) 0.20
ACEI indicates angiotensin-converting enzyme inhibitor; OR, odds ratio; and CI, confidence interval.
*Models were adjusted for propensity score of ACEI treatment and Acute Physiology and Chronic Health Evaluation II (APACHE II) Acute Physiology Scores (partial).
It was possible that 1 outcome occurred in the same patient. Fifty-eight covariates of demographics, medical history, and preoperative, intraoperative, and/or early
postoperative factors were included in the propensity score model for ACEI treatment (see the online-only Data Supplement). APACHE II–Acute Physiology score (partial)
was calculated by 9 physiological variables: temperature (rectal), mean arterial pressure, heart rate, oxygenation, arterial pH, serum sodium, serum potassium, serum
creatinine, and hematocrit.
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ings, ACEI therapy in cardiac surgery is most valuable when
it is provided perioperatively, and importantly, its immediate
withdrawal after surgery can be associated with poor out-
comes. In comparing the continuation group with the imme-
diate withdrawal cohort, we observed a 50% reduction of
odds in overall complications, including a 61% and 46%
reduction in CHF and MI, respectively. Furthermore, ACEI
withdrawal was related to increased odds of renal event by
113%.
Studies on perioperative use of ACEI in cardiac surgery
have yielded both promising and conflicting messages. Ear-
lier reports suggested marked vasoplegia after the induction
of anesthesia and in the setting of CPB necessitating greater
vasopressor and fluid resuscitation.32,33 As a result, with-
drawal of ACEI therapy before cardiac surgery became a
common practice. Subsequent studies addressing such hemo-
dynamic and other relevant clinical effects have since chal-
lenged this view. Pigott et al21 found that regular withdrawal
of ACEI preoperatively resulted in higher mean arterial
pressure and increased need for antihypertensive therapy in
the early period after CPB. Licker et al34 and Ryckwaert et
al22 also could not demonstrate clinically significant vasople-
gia in patients receiving long-term ACEI. Nevertheless, a
recent report from the United Kingdom found that the
majority of surgeons there continue to opine that the use of
ACEI in cardiac surgery leads to hemodynamic instability
and an increased need for fluids and vasoactive drugs.35 Of
interest, our cohort of patients on continuous ACEI therapy
did have higher requirement for vasopressor support after
CPB; however, there were no appreciable differences in
hemodynamic parameter or need for assist devices for a
low-output state either intraoperatively or postoperatively
between this group and the no ACEI treatment group.
Decisions prompting more frequent therapy with cardiovas-
cular support in the continuous ACEI group may very well
been influenced by notable differences in EuroSCORE and
APACHE II (P0.001), both suggestive that this group had
a higher operative risk. In part, the decision may be indicative
of the inherent bias in selection of inotropes and vasopressors
after CPB, which is both center specific and clinician spe-
cific. However, we attempted to control for such potential
practice bias by excluding the “routine” use of inotropes and
vasopressors and by including the need for2 vasoactive and
cardioactive agents. As demonstrated in Table 4, no clinically
significant differences in blood pressure, cardiac output, and
extubation times were noted among the groups.
The RAAS is an important contributor to pathological
vascular remodeling.36,37 Thus, inhibition of the RAAS with
ACEIs alone or in combination with angiotensin receptor
blockers should be an effective modality for lowering peri-
operative cardiovascular risks. More recently, the benefits of
ACEIs appear to be systemic and independent of its blood
pressure effects, providing cerebrovascular and renovascular
protection.17–20 Because of these secondary actions of ACEIs
(endothelial protective effects), there has been a shift in
therapeutic approach from the initial pharmacological-
antihypertensive to a therapeutic approach having a biologi-
cal (nonhemodynamic) underpinning.30
CPB, a potent mediator of inflammation, is associated with
marked activation of the RAAS.38 These, together with
activation of the sympathoadrenal and hemostatic pathways,
may provide the groundwork for microvascular injury and
organ dysfunction.12,39 Thus, inhibition of ACE can mitigate
angiotensin production and, importantly, may improve mi-
crocirculatory perfusion via the aforementioned mecha-
nisms.40,41 Additionally, ACEI added to cardioplegia solution
has been shown to directly reduce ischemia/reperfusion
injury, to reduce myocardial ACE activity, and to provide
antiarrhythmic effects.40
Clinical Implications
In this large multicenter, international study, we provide new
and important information on the practice pattern of ACEI
use in cardiac surgery. The associated improvement in
outcomes with ACEI therapy was not surprising given the
well-known benefits of blocking the RAAS; however, it is
alarming to learn that clinicians chose to immediately discon-
tinue ACEI therapy in nearly 50% of patients after cardiac
Table 3. Multivariable Logistic Regression for the Composite
Outcome in 4224 Study Patients
Risk Factor
Adjusted Odds Ratio
(95% CI) P
ACEI treatment
Continuation vs no ACEI 0.58 (0.44–0.76) 0.001
Addition vs no ACEI 0.58 (0.39–0.85) 0.006
Withdrawal vs no ACEI 1.70 (1.36–2.13) 0.001
Continuation vs withdrawal 0.58 (0.39–0.85) 0.006
History of hypertension 1.28 (1.03–1.59) 0.03
History of carotid disease 1.49 (1.14–1.93) 0.003
History of renal disease 1.39 (1.08–1.80) 0.01
Warfarin in the past week of admission 1.74 (1.22–2.47) 0.002
Congestive heart failure on admission
or preoperative
1.79 (1.20–2.66) 0.004
Creatinine on admission (maximum)
1.3 mg/dL
1.48 (1.15–1.90) 0.002
Intubation and reintubation 24 h
(within 48 h)
2.32 (1.83–2.95) 0.001
Assist device use for low cardiac
output, ischemic, or angina
intraoperatively or on RDOS
3.19 (1.78–5.70) 0.001
Fluid intake intraoperative to RDOS 1.009 (1.005–1.012) 0.001
EuroSCORE 1.07 (1.03–1.10) 0.001
APACHE II Acute Physiology score
(partial)
1.05 (1.01–1.09) 0.006
CI indicates confidence interval; ACEI, angiotensin-converting enzyme inhib-
itor; RDOS remaining day of surgery; EuroSCORE, European System for Cardiac
Operative Risk Evaluation; and APACHE II, Acute Physiology and Chronic Health
Evaluation II. Excluded were 502 patients with missing values for at least 1
covariate. The Hosmer–Lemeshow goodness-of-fit 2 test statistic was 7.97
(P0.44). The C index for the model was 0.72. Direct comparison of ACEI
treatment groups by contrast functions on model parameters demonstrated
decreased risk with ACEI continuation compared with ACEI withdrawal (odds
ratio, 0.58; 95% CI, 0.39–0.85; P0.006). Odds ratio for fluid intake
intraoperatively to RDOS was calculated per 100-mL increment. Odds ratio of
EuroSCORE was calculated per 1-unit increment. Odds ratio of APACHE II Acute
Physiology score (partial) was calculated per 1-unit increment.
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surgery. This pattern of practice was associated with major
vascular complications. Immediate withdrawal of ACEI ther-
apy may be particularly harmful in the context of cardiac
surgery because an abrupt rebound in ACE activity may
further compromise microcirculatory flow. Westendorp et
al41 studied the effects of ACEI therapy in the setting of acute
MI in rats and found that the endothelium-dependent vasore-
laxation dissipates rapidly after ACEI withdrawal. Kennedy
et al42 and Wallace et al25 addressed the consequences of drug
withdrawal postoperatively and in a general surgical unit and
provided evidence that withdrawal of regular cardiovascular
medicines adds to the risk of the surgery and complicates
outcomes.
Limitations
Our prospective study may be limited by a number of factors,
including its observational design and the absence of proto-
cols to guide clinical management. However, with nearly
2000 patients in each group (ACEI and no ACEI), there is
sufficient power to investigate both morbid and fatal vascular
complications. Importantly, the data are robust, were prospec-
tively gathered, and represent an international cohort from 70
institutions. This international experience makes the data very
relevant, because use of ACEI has increased in the last
decade43 although its pattern of withdrawal remains high.35
Another relevant criticism is the significant difference in
clinical characteristics between the ACEI group and the no
ACEI group, which suggests a higher operative risk profile
(Euro-SCORE) for the ACEI-treated group. To compensate
for the large variability in patient characteristics, the associ-
ations between ACEI therapy and outcomes were performed
with adjustments for propensity score, Euro-SCORE, and
APACHE II (modified) score. The APACHE II score was
used to determine the severity of illness within the first 24
hours after each patient was admitted to the ICU. Finally, we
cannot account for the clinical rational that led to withdrawal
of ACEI therapy in nearly half of the patients. The groups had
similar cardiac outputs in the ICU and clinically similar
systolic blood pressure, extubation times, and need for
nonroutine inotropes (less for the no ACEI group), although
there was a striking difference in use of assist devices and in
transfusion of red blood cells in the withdrawal group
intraoperatively.
Conclusions
Our multicenter, multinational study suggests that in patients
undergoing CABG surgery with CPB, continuation of ACEI
Figure 2. Kaplan–Meier survival analysis of event-free status by
angiotensin-converting enzyme inhibitor (ACEI) therapy. The
curves show data of 30-day in-hospital composite event-free
status. The P value shown is for the comparison of Kaplan–
Meier survival function among the 4 groups. The P value was
calculated from the log-rank test.
Table 4. Characteristics in the 24 Hours After Intensive Care Unit Arrival by Angiotensin-Converting Enzyme Inhibitor Treatment Groups
Characteristics
No ACEI
(n2043)
Addition
(n343)
Continuation
(n915)
Withdrawal
(n923) P* P† P‡
Mean cardiac output in the 24 h after ICU arrival, L/min 0.54 0.84 0.93
Median 5.57 5.51 5.61 5.56
Quartiles 1–3 4.75–6.48 4.62–6.48 4.75–6.60 4.76–6.47
Mean SBP in the 24 h after ICU arrival, mm Hg 0.001 0.001 0.001
Median 116.2 121.8 120.6 115.7
Quartiles 1–3 109.3–123.9 113.4–130.0 112.9–128.4 108.7–123.7
Intubation time, h 0.001 0.001 0.36
Median 13.2 16.4 15.6 15.4
Quartiles 1–3 9.7–18.4 12.0–22.7 11.5–22.2 11.2–21.3
2 Simultaneous nonroutine inotropes on RDOS, n (%) 282 (13.8) 92 (26.8) 257 (28.1) 256 (27.7) 0.001 0.001 0.18
Assist device use for low cardiac output or ischemic or
angina, n (%)
35 (1.7) 5 (1.5) 12 (1.3) 35 (3.8) 0.31 0.92 0.001
Intraoperative or on RDOS, n (%)
Red blood cell transfusion in 24 h after ICU arrival, n (%) 762 (37.3) 149 (43.3) 368 (40.2) 446 (48.3) 0.09 0.004 0.001
ACEI indicates angiotensin-converting enzyme inhibitor; ICU, intensive care unit; SBP, systolic blood pressure; and RDOS, remaining day of surgery. Bonferroni
correction for multiple testing requires P0.017 for significance.
*P was calculated from the Wilcoxon rank-sum test for continuous variables or the 2 test for categorical variables for the comparison of the no ACEI group vs
the ACEI continuation group.
†P was calculated for the comparison of the no ACEI group vs the ACEI addition group.
‡P was calculated for the comparison of the ACEI continuation group vs the ACEI withdrawal group.
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therapy early after surgery or adding ACEI de novo postop-
eratively can be associated with a marked improvement in
cardiovascular and renal outcomes. Conversely, a practice of
withdrawing of ACEI treatment postoperatively is associated
with poor in-hospital fatal and nonfatal outcomes.
Source of Funding
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CLINICAL PERSPECTIVE
Despite significant improvement in both surgical and medical management of coronary artery bypass graft patients, many
experience significant perioperative morbidity that adversely affects quality of life and length of hospitalization and
increases resource use. Angiotensin-converting enzyme inhibitors (ACEIs) have been proven effective in the care of
cardiovascular patients with hypertensive heart disease and congestive heart failure; however, effect of ACEI on survival
in patients undergoing coronary artery bypass graft surgery is equivocal. Unfortunately, ACEI treatment is usually held up
before coronary artery bypass graft, primarily because of historical reports linking it to hemodynamic instability during the
perioperative period and a larger need for vasoactive drug use and fluid administration. To address these issues, we
designed a prospective, international, multi-institutional study that allowed determination of the impact of the current
practice pattern of ACEI use on morbidity and mortality after coronary artery bypass graft surgery. We showed that
continuation of ACEI therapy early after surgery or adding ACEI de novo postoperatively can be associated with marked
improvement in cardiovascular and renal outcomes. Conversely, a practice of withdrawing ACEI treatment postoperatively
is associated with poor in-hospital nonfatal outcomes. The associated improvement in outcomes with ACEI therapy was
not surprising, given the well-known benefits of blocking the renin-angiotensin-aldosterone system; however, it is alarming
to learn that clinicians chose to acutely discontinue ACEI therapy in nearly 50% of patients after cardiac surgery. The
present work confirms that acute withdrawal of ACEI therapy may be particularly harmful in the context of cardiac surgery,
and attention to restore ACEI therapy soon after operation should be encouraged.
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SUPPLEMENTAL MATERIAL 
Appendix 1.  
The IREF is an independent nonprofit foundation, formed in 1987, that develops 
clinical investigators via observational studies and clinical trials addressing ischemic 
injury of the heart, brain, kidney, and gastrointestinal tract. The IREF provided all 
funding for execution of the study, collection of the data, and analysis and 
publication of the findings. The Multicenter Study of Perioperative Ischemia 
Research Group, formed in 1988, is an association of 160 international medical 
centers located in 23 countries organized through and supported by grants from the 
IREF. 
The following institutions and persons coordinated the Multicenter Study of 
Perioperative Ischemia Research Group EPI‐II study. Study Chairman—D. Mangano; 
Senior Editors—J. Levin, L. Saidman; Study Design and Analysis Center: Ischemia 
Research and Education Foundation—P. Barash, C. Dietzel, A. Herskowitz, K. Huang, 
Y. Miao, I. C. Tudor, S. Wang, Y. Weng; Editorial/Administrative Group—D. Beatty, I. 
Lei, B. Xavier. 
The following institutions and persons participated in the McSPI EPI‐II Study. Centers 
and investigators: United States—University of Chicago, Weiss Memorial Hospital—
S. Aronson; Beth Israel Hospital—M. Comunale; Massachusetts General—M. 
D'Ambra; University of Rochester — M. Eaton; Baystate Medical Center—R. 
Engelman; Baylor College of Medicine—J. Fitch; Duke Medical Center—K. Grichnik; 
UTHSCSA‐Audie Murphy VA, UTHSCSA‐University Hospital—C. B. Hantler; St. Luke's 
Roosevelt Hospital—Z. Hillel; New York University Medical Center—M. Kanchuger, J. 
Ostrowski; Stanford University Medical Center—C. M. Mangano; Yale University 
School of Medicine—J. Mathew, M. Fontes, P. Barash; University of Wisconsin—M. 
McSweeney, R. Wolman; University of Arkansas for Medical Sciences—C. A. 
Napolitano; Discovery Alliance, Inc.—L. A. Nesbitt; VA Medical Center, Milwaukee—
N. Nijhawan; Texas Heart Institute, Mercy Medical Center—N. Nussmeier; University 
of Texas Medical School, Houston—E. G. Pivalizza; University of Arizona—S. Polson; 
Emory University Hospital—J. Ramsay; Kaiser Foundation Hospital—G. Roach; 
Thomas Jefferson University Hospital, MCP Hahnemann University Hospital— 
N. Schwann; VAMC Houston—S. Shenaq; Maimonides Medical Center—K. Shevde; 
Mt. Sinai Medical Center—L. Shore‐Lesserson, D. Bronheim; University of Michigan—
J. Wahr; University of Washington—B. Spiess, I. Wright; VA Medical Center, S. F.—A. 
Wallace; Austria—University of Graz—H. Metzler; Canada—University of British 
Columbia—D. Ansley, J. P. O'Connor; The Toronto Hospital—D. Cheng; Laval 
Hospital, Quebec—D. Côte; Health Sciences Centre‐University of Manitoba—P. Duke; 
University of Ottawa Heart Institute—J. Y. Dupuis, M. Hynes; University of Alberta 
Hospital—B. Finegan; Montreal Heart Institute—R. Martineau, P. Couture; St. 
Michael's Hospital, University of Toronto—D. Mazer; Colombia—Fundacion Clinico 
Shaio—J. C. Villalba, M. E. Colmenares; France—CHRU Le Bocage—C. Girard; Hospital 
Pasteur—C. Isetta; Germany—Universität Wrzburg—C. A. Greim, N. Roewer; 
Universität Bonn—A. Hoeft; University of Halle—R. Loeb, J. Radke; Westfalische 
Wilhelms‐Universität Munster—T. Mollhoff; Universität Heidelberg—J. Motsch, E. 
Martin; Ludwig‐Maximillians Universität—E. Ott; Universität Krankenhaus 
Eppendorf—J. Scholz, P.Tonner; Georg‐August Universität Göttingen—H. Sonntag; 
Ludwig‐Maximillians Universität (Department of Cardiac Surgery)—P. Ueberfuhr; 
Hungary—Orszagos Kardiologiai Intezet—A. Szekely; India—Escorts Heart Institute—
R. Juneja; Apollo Hospital—G. Mani; Israel—Hadassah University Hospital—B. 
Drenger, Y. Gozal, E. Elami; Italy—San Raffaele Hospital, Universita de Milano—C. 
Tommasino; Mexico—Instituto Nacional de Cardiologia—P. Luna; The Netherlands—
University Hospital Maastricht—P. Roekaerts, S. DeLange; Poland—Institute of 
Cardiology—R. Pfitzner; Romania—Institute of Cardiology—D. Filipescu; Thailand—
Siriraj Hospital—U. Prakanrattana; United Kingdom—Glenfield Hospital—D. J. R. 
Duthie; St. Thomas' Hospital—R. O. Feneck; The Cardiothoracic Centre, Liverpool—
M. A. Fox; South Cleveland Hospital—J. D. Park; Southampton General Hospital—D. 
Smith; Manchester Royal Infirmary—A. Vohra; Papworth Hospital— A. Vuylsteke, R. 
D. Latimer. 
   
Appendix 2.  
58 Propensity Score Covariates for Preoperative and/or Postoperative ACEI Therapy: 
Demographics (7 Variables) 
Age over 60 and per 5yr thereof and over 80 
Female gender 
Private insurance 
Ethnicity–African American or Hispanic or American Indian 
Education–Some college (at least) 
Known history of IV drug use 
Known history of alcohol abuse 
 
Medical History (18 Variables) 
Unstable angina 
Congestive heart failure 
Myocardial infarction 
Dysrhythmia 
Hypertension 
Valve disease 
Neurologic dysfunction (stroke or transient ischemic attack) 
Carotid disease 
Syncope 
Pulmonary disease 
Renal disease  
Diabetes 
Peripheral vascular disease 
Hematologic disorder 
CABG surgery 
Other non‐cardiac surgery 
Noncoronary angioplasty/stent 
Warfarin in the past week of admission 
Admission/Preoperative Factor (13 Variables) 
Intra‐aortic balloon pump 
Congestive heart failure 
Pulse pressure 
Creatinine (maximum) > 1.3 mg/dL 
Medications– Antiarrhythmics 
Medications–Anticoagulants 
Medications–Bronchodilators 
Medications–Calcium Channel Blockers 
Medications–Diuretics 
Medications–Inotropes/Vasoconstrictors 
Medications–Peripheral vasodilators 
Medications–Antithrombotics 
Medications–Electrolyte Supplements 
Surgical/Intraoperative/Early Postoperative Factor (20 Variables) 
Urgent surgery 
Use PA Catheter 
Cardioplegia 
Pump flow bypass techniques (pulsatile vs. nonpulsatile) 
Pump type bypass techniques (roller vs. centrifugal) 
Oxygenator type bypass techniques (bubble vs. membrane) 
Number of bypass grafts 
Cardiopulmonary bypass time  
Intraoperative transfusion of red blood cell 
Intraoperative transfusion of fresh frozen plasma 
Intraoperative transfusion of platelets 
Mean arterial pressure (maximum) in the first 24 hours after ICU arrival 
Intubation and/or re‐intubation ≥ 24 hours (within 48 hours after the beginning of surgery) 
Intraoperative–Postoperative prior to the 1st occurrence of the composite outcome: Use 
assist  
     device for low cardiac output/angina/ischemia 
Intraoperative– Postoperative prior to the 1st occurrence of the composite outcome: 
Medications– 
    Beta Blockers 
Intraoperative– Postoperative prior to the 1st occurrence of the composite outcome: 
Medications– 
    Calcium Channel Blockers 
Intraoperative– Postoperative prior to the 1st occurrence of the composite outcome: 
Medications– 
    Diuretics 
Intraoperative– Postoperative prior to the 1st occurrence of the composite outcome: 
Medications– 
    2 or more simultaneous Inotropes 
Postoperative prior to the 1st occurrence of the composite outcome: Medications–Statins 
Intraoperative–remaining day of surgery: fluid intake  
 
 
 
 
